<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: EUROCARE collected data from population-based <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> registries in 20 European countries </plain></SENT>
<SENT sid="1" pm="."><plain>We used this data to compare <z:e sem="disease" ids="C0278704" disease_type="Neoplastic Process" abbrv="">childhood cancer</z:e> survival time trends in Europe </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: Survival in 44,129 children diagnosed under the age of 15 years during 1983 to 1994 was analyzed </plain></SENT>
<SENT sid="3" pm="."><plain>Sex- and age-adjusted 5-year survival trends for 10 common <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> and for <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> combined were estimated for five regions (West Germany, the United Kingdom, Eastern Europe, Nordic countries, and West and South Europe) and Europe as a whole </plain></SENT>
<SENT sid="4" pm="."><plain>Europe-wide trends for 14 rare <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> were estimated </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: For <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> combined, 5-year survival increased from 65% for diagnoses in 1983 to 1985 to 75% in 1992 to 1994 </plain></SENT>
<SENT sid="6" pm="."><plain>Survival improved for <z:hpo ids='HP_0000001'>all</z:hpo> individual <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> except <z:hpo ids='HP_0002861'>melanoma</z:hpo>, <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo>, and <z:hpo ids='HP_0002890'>thyroid carcinoma</z:hpo>; although for <z:hpo ids='HP_0009919'>retinoblastoma</z:hpo>, <z:hpo ids='HP_0006765'>chondrosarcoma</z:hpo>, and <z:hpo ids='HP_0100244'>fibrosarcoma</z:hpo>, improvements were not significant </plain></SENT>
<SENT sid="7" pm="."><plain>The most marked improvements (50% to 66%) occurred in Eastern Europe </plain></SENT>
<SENT sid="8" pm="."><plain>For common <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, the greatest improvements were for <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, with risk of dying reducing significantly by 5% to 6% per year </plain></SENT>
<SENT sid="9" pm="."><plain>Survival for <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> improved significantly from 57% to 65%, with risk reducing by 3% per year </plain></SENT>
<SENT sid="10" pm="."><plain>Risk reduced by 4% per year for <z:hpo ids='HP_0003006'>neuroblastoma</z:hpo> and 3% per year for <z:e sem="disease" ids="C0027708" disease_type="Neoplastic Process" abbrv="">Wilms' tumor</z:e> and <z:hpo ids='HP_0002859'>rhabdomyosarcoma</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>The survival gap between regions reduced over the period, particularly for <z:hpo ids='HP_0011009'>acute</z:hpo> nonlymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, and <z:hpo ids='HP_0002859'>rhabdomyosarcoma</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>For rare Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, <z:hpo ids='HP_0002884'>hepatoblastoma</z:hpo>, gonadal <z:mpath ids='MPATH_310'>germ cell tumors</z:mpath>, and nasopharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp>, risk reductions were at least 10% per year </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSION: These gratifying improvements in survival can often be plausibly related to advances in treatment </plain></SENT>
<SENT sid="14" pm="."><plain>The prevalence of European adults with a history of <z:e sem="disease" ids="C0278704" disease_type="Neoplastic Process" abbrv="">childhood cancer</z:e> will inevitably increase </plain></SENT>
</text></document>